Sakar Healthcare Ltd is making significant strides in the global pharmaceutical market by entering nine agreements to boost oncology product exports and finalizing seven additional agreements with partners from Europe, South America, and Latin America. These developments highlight the company’s commitment to expanding its reach and enhancing its product portfolio in the oncology segment.
The agreements cover a range of business models, including licensing, manufacturing, and product supply, and involve collaborations with key players in the pharmaceutical industry. Sakar’s EU GMP-certified oncology manufacturing unit, located in Gujarat, India, has been instrumental in driving these partnerships, offering high-quality formulations such as liquid injections, lyophilized injections, tablets, and capsules.
The company’s focus on anti-cancer products aligns with its vision to address critical healthcare needs and establish a strong foothold in international markets. By leveraging its expertise and regulatory approvals, Sakar Healthcare aims to create a robust business matrix that spans multiple continents.
Key Highlights:
-
- Sakar Healthcare enters nine agreements to boost oncology product exports.
-
- Seven agreements under final negotiations with partners from Europe, South America, and Latin America.
-
- Collaborations include licensing, manufacturing, and product supply for anti-cancer products.
-
- EU GMP-certified oncology unit plays a pivotal role in global partnerships.
Sources: Sakar Healthcare Ltd, Economic Times, Business Standard.